Literature DB >> 12108451

The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia.

Dong Soon Kim1, Bin Yoo, Jin Sung Lee, Eun Kyung Kim, Chae Man Lim, Sang Do Lee, Younsuck Koh, Woo Sung Kim, Won Dong Kim, Thomas V Colby, Masanori Kitiaichi.   

Abstract

BACKGROUND: The prognosis of pulmonary fibrosis associated with scleroderma (PF-SSc) has been reported to be significantly better than that of IPF. Because the nonspecific interstitial pneumonia-pattern (NSIP), a newly defined subgroup of idiopathic interstitial pneumonias (IIP), has better prognosis than the usual interstitial pneumonia pattern (UIP), we postulated that NSIP may occur more frequently than UIP in patients with scleroderma who develop fibrosis.
METHOD: We reviewed the pathologic, radiologic and clinical outcomes in 19 patients with PF-SSc. Two pulmonary pathologists reclassified the histopathology of surgical lung biopsies (SLBx) and consensus diagnosis was achieved in all patients.
RESULTS: Thirteen patients had NSIP, five had UIP, and remained one showed only nondiagnostic honeycombing. No significant difference was noted in the initial pulmonary function test (PFT), bronchoalveolar lavage (BAL) findings, or other clinical parameters between UIP and NSIP groups. Comparison of the clinical outcome of 12 patients who were followed for more than 12 months (mean: 34.5 +/- 26.0 months) suggested a better prognosis for NSIP than UIP. Five of the eight NSIP patients improved and three were stable, whereas in patients with UIP, one worsened and three were stable.
CONCLUSION: NSIP seems to be the major histopathologic pattern in patients with PF-SSc.

Entities:  

Mesh:

Year:  2002        PMID: 12108451

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  34 in total

1.  Lower-lobe shrinkage relative to total lung volume in collagen vascular diseases.

Authors:  M Watanabe; T Igishi; N Burioka; J Kurai; Y Fukuoka; K Kato; A Yamasaki; Y Hasegawa; R Okazaki; E Shimizu
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders.

Authors:  Toshio Sato; Jiro Fujita; Ichiro Yamadori; Yuji Ohtsuki; Takeo Yoshinouchi; Shuji Bandoh; Michiaki Tokuda; Toshihiko Ishida
Journal:  Rheumatol Int       Date:  2005-11-08       Impact factor: 2.631

Review 3.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

Review 4.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

5.  Autoimmune-featured interstitial lung disease: a distinct entity.

Authors:  Rekha Vij; Imre Noth; Mary E Strek
Journal:  Chest       Date:  2011-05-12       Impact factor: 9.410

6.  Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Authors:  Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2018-11

Review 7.  Imaging lung disease in systemic sclerosis.

Authors:  Diane Strollo; Jonathan Goldin
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

8.  Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia.

Authors:  Bo Hyoung Kang; Jin Kyeong Park; Jae Hyung Roh; Jin Woo Song; Chang Keun Lee; Miyoung Kim; Se Jin Jang; Thomas V Colby; Dong Soon Kim
Journal:  J Korean Med Sci       Date:  2013-05-02       Impact factor: 2.153

Review 9.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  [Histomorphology of interstitial lung disease and pulmonary vasculitis].

Authors:  I Bittmann; K Holl-Ulrich
Journal:  Z Rheumatol       Date:  2009-10       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.